April 14, 2021 10:26 AM EDT

Amylyx to move forward with ALS program in Europe, but FDA wants another look; Humacyte adds $50M in debt financing

John Carroll

Editor & Founder

Max Gelman

Senior Editor

Josh Sullivan

Amylyx is one of several companies looking to break through in the tough ALS field, and Wednesday they announced they’re moving forward with regulatory plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amylyx to move forward with ALS program in Europe, but FDA wants another look; Humacyte adds $50M in debt financing

John Carroll

Editor & Founder

Max Gelman

Senior Editor

Josh Sullivan

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Exclusive: Florida cancer biotech raises $100M Series A

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Amy­lyx to move for­ward with ALS pro­gram in Eu­rope, but FDA wants an­oth­er look; Hu­ma­cyte adds $50M in debt fi­nanc­ing

Editor & Founder

Senior Editor

Sign up to read this article for free.

more like this

Amylyx to move forward with ALS program in Europe, but FDA wants another look; Humacyte adds $50M in debt financing